After a decade of above-average sales growth, Boehringer Ingelheim GmbH expects revenue will be flat in 2010, as it loses patent protection for some important drugs. In the current year, it plans to invest heavily in R&D which will impact on income.
After a decade of above-average sales growth, Boehringer Ingelheim GmbH expects revenue will be flat in 2010, as it loses patent protection for some important drugs. In the current year, it plans to invest heavily in R&D which will impact on income.